METROPOLIS2023-10-012023-12-31 METROPOLIS2023-10-012023-12-31 METROPOLIS2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member METROPOLIS2023-10-012023-12-31in-bse-fin:OneOperatingExpenses02Member METROPOLIS2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member METROPOLIS2023-10-012023-12-31in-bse-fin:FourOperatingExpenses02Member METROPOLIS2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 542650 METROPOLIS NOTLISTED Metropolis Healthcare Limited Equity 2023-04-01 2024-03-31 2024-02-02 2024-01-26 INR Lakhs Third quarter 14:55:00 18:20:00 2024-02-02 2024-02-02 Not applicable Single segment Pathology Services 2023-10-01 2023-12-31 Unaudited Consolidated 2911171000.00 23061000.00 2934232000.00 572490000.00 0.00 0.00 695054000.00 53074000.00 249906000.00 995159000.00 2565683000.00 368549000.00 0.00 368549000.00 102476000.00 -6818000.00 95658000.00 0.00 272891000.00 0.00 0.00 0.00 0.00 272891000.00 -4043000.00 268848000.00 271584000.00 1307000.00 267557000.00 1291000.00 102445000.00 2 5.30 5.28 0.00 0.00 5.30 5.28 1. Metropolis Healthcare Limited (the 'Company’ or the ‘Parent') and its subsidiaries (referred collectively as the ‘Group’) are primarily involved in providing pathology and related healthcare services. 2. The consolidated financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ( Ind AS ) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. 3. The consolidated financial results of the Group have been reviewed by the Audit Committee at their meeting held on 02 February 2024 and thereafter approved by the Board of Directors at their meeting held on 02 February 2024. The statutory auditors have issued unmodified review report on the above consolidated financial results. 4. Disclosure of segment –wise information is not applicable, as pathology services is the Group’s only business segment. 5. The Board of Directors of the Company, at their meeting held on 11 February 2022, accorded in-principle approval for the voluntary liquidation of Dr. Ganesan’s Hitech Diagnostic Centre Private Limited (‘Hitech’), a wholly owned subsidiary of the Company, to be carried out under the provisions of Insolvency and Bankruptcy Code, 2016. The Board of Directors of Hitech in their meeting dated 01 April 2022 and the members of Hitech in their Extra Ordinary General meeting held on 01 April 2022 have accorded their approval for consolidation of the business of Hitech through voluntary liquidation process. Pursuant to the ongoing liquidation process, the liquidator of Hitech has transferred the entire business undertaking to the Company on a going concern basis on and with effect from 04 June 2022. 6. On November 04, 2023, the Board of Directors of the Company approved grant of 2000 Restricted Stock Units (RSU) on the recommendation of the Nomination and Remuneration Committee, pursuant to the Metropolis – Restrictive Stock Unit Plan – 2020 to eligible employees of the Company. This is in addition to the RSU's approved under Restrictive Stock Unit Plan – 2020 to eligible employees of the Company / subsidiaries in the previous quarters. 7. On 16 November 2022, the Income Tax department conducted searches at the premises of the Company and some of its subsidiaries. No assets of the Company or its subsidiaries were seized during this process. The Company has been providing from time to time the information and clarifications sought by the Income Tax authorities. Subsequently, including during the current quarter, the Company and some of its subsidiaries have received notices under sections 142(1), 143(2), 147 and 148 of the Income Tax Act,1961, that provide for the reopening of past assessment proceedings. Presently, there is no demand, and accordingly, no adjustments have been made in the financial results. 8. Other expenses for the quarter and nine months period ended 31 December 2023 includes Rs 418.85 lakhs on account of provision for doubtful debtors as an outcome of investigation relating to a whistle blower complaint. For detailed notes, kindly refer the results of the Group which are made available at www.metropolisindia.com, www.nseindia.com and www.bseindia.com. Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 8767088000.00 65776000.00 8832864000.00 1754743000.00 0.00 0.00 2043180000.00 169664000.00 680505000.00 2943203000.00 7591295000.00 1241569000.00 0.00 1241569000.00 356589000.00 -34316000.00 322273000.00 0.00 919296000.00 0.00 0.00 0.00 0.00 919296000.00 -67660000.00 851636000.00 914093000.00 5203000.00 846463000.00 5173000.00 102445000.00 2 17.85 17.78 0.00 0.00 17.85 17.78 Laboratory testing charges 20900000.00 Other expenses 974259000.00 Laboratory testing charges 73203000.00 Other expenses 2870000000.00 7366000.00 22098000.00 -3323000.00 45562000.00